Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel, Temozolomide, Radiation, and Bevacizumab in High Grade Glioma
NCT00660621Phase 2Unknown
- Sponsor
- Kentuckiana Cancer Institute
- Start
- Apr 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine and bevacizumab in high-grade glioma (HGG), sponsored by Kentuckiana Cancer Institute. Primary endpoint: Safety and efficacy of concomitant limited field radiation therapy and temozolomide, followed by dose dense temozolomide and bevacizumab at 6 months. Status: unknown.
02
Drugs
carmustinebevacizumab
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT00660621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660621.